Almotriptan Malate Patent Expiration

Almotriptan Malate is Used for relieving symptoms of migraines. It was first introduced by Janssen Pharmaceuticals Inc in its drug Axert on May 7, 2001. 4 different companies have introduced drugs containing Almotriptan Malate.


Almotriptan Malate Patents

Given below is the list of patents protecting Almotriptan Malate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Axert US5565447

(Pediatric)

Indole derivatives Nov 07, 2015

(Expired)

Janssen Pharms
Axert US5565447 Indole derivatives May 07, 2015

(Expired)

Janssen Pharms



Almotriptan Malate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Almotriptan Malate Generic API Manufacturers

Several generic applications have been filed for Almotriptan Malate. The first generic version for Almotriptan Malate was by Teva Pharmaceuticals Usa and was approved on Jul 7, 2015. And the latest generic version is by Ajanta Pharma Ltd and was approved on Mar 3, 2016.

Given below is the list of companies who have filed for Almotriptan Malate generic, along with the locations of their manufacturing plants worldwide.